Company / Current Liabilities
Intellia Therapeutics, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$103.9M
FY2025
5-year range
$103.9M / $126.6M
FY2021-FY2025
Trend
-6.3%
vs FY2024
Sector context
#127 of 165
Health Care
What the data says
Intellia Therapeutics, Inc.'s current liabilities of $104M is lower than 77% of companies in the Health Care sector (FY2025). Current Liabilities has declined for 3 consecutive years, from $127M in FY2022 to $104M in FY2025.
Based on SEC 10-K filings.
$104M in FY2025 with a 5-year CAGR of +10.1%.
Improved from $115M to $104M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- -6.4%
- 5-Year CAGR
- +10.1%
- 10-Year CAGR
- -
Sector benchmark
Top 23% in Health CareTop 23% of 165This company $103.9M Sector average $4.4B
▼
-97.7% below sector average
Key checks
Key Insights
- Intellia Therapeutics, Inc.'s current liabilities has declined for 3 consecutive years.
- 5-year CAGR of +10.1%, indicating consistent growth.
- In FY2025, current liabilities decreased 6.3% year-over-year.
- Ranks #127 out of 165 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $103.9M | -6.3% |
| FY2024 | $110.9M | -3.8% |
| FY2023 | $115.2M | -9.0% |
| FY2022 | $126.6M | +0.6% |
| FY2021 | $125.8M | +95.8% |
| FY2020 | $64.3M | +80.3% |
| FY2019 | $35.6M | -12.2% |
| FY2018 | $40.6M | +29.4% |
| FY2017 | $31.4M | +2.0% |
| FY2016 | $30.7M | +187.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026